UK-based pharmaceutical company GSK has reported updated results from a Phase II study of Jemperli (dostarlimab) for locally advanced mismatch repair deficient (dMMR) rectal cancer.
The drug candidate was found to be 100% effective in treating all patients who were enrolled in the trial.
Go deeper with GlobalData
The supported collaborative study was conducted in collaboration with Memorial Sloan Kettering Cancer Center.
In the trial, Jemperli was assessed as a first-line therapy that could replace surgery for dMMR locally advanced rectal cancer.
The trial’s findings showed that all 42 patients who completed the treatment with dostarlimab showed a 100% clinical complete response rate (cCR) with no evidence of tumours or complete pathologic response.
A sustained clinical complete response was observed in the first 24 subjects, with a median follow-up of 26.3 months.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataDostarlimab’s safety and tolerability profile aligned with the already reported data without any adverse events of Grade III or higher observed.
Jemperli is a programmed death receptor-1 (PD-1)-blocking antibody that is being assessed in various immuno-oncology-based research and development programmes.
The drug is not currently approved for the frontline treatment of locally advanced dMMR rectal cancer anywhere in the world.
GSK is actively pursuing further studies through its AZUR clinical trial programme, focusing on advanced and metastatic stages of dMMR/MSI-H colorectal cancer.
GSK oncology R&D global head and senior vice-president Hesham Abdullah said: “The data showing no evidence of disease in 42 patients is remarkable.
“These results bring us one step closer to understanding the potential of dostarlimab in this curative-intent setting for patients with dMMR locally advanced rectal cancer.
“We look forward to evaluating dostarlimab in certain colorectal cancers in our ongoing AZUR-1 and AZUR-2 registrational studies.”
Last month, GSK announced positive data from two Phase III trials of its asthma candidate depemokimab.
